ArticleBiomarker research2025

USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition.

Ji Hye Shin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.